Literature DB >> 30814348

Patient Perceptions of Antihypertensive Use as a Dementia Prevention Strategy: A Mixed-Method Analysis of a Web-Based Survey.

Zachary A Marcum1, Sarah D Hohl2, Shelly L Gray1, Doug Barthold1, Paul K Crane3, Eric B Larson4.   

Abstract

We administered a mixed-method survey to 1,661 patients in a large health system to assess preferences toward antihypertensive use for dementia prevention. If a specific antihypertensive medication was shown to prevent or delay dementia, the vast majority (>90%) of respondents currently taking an antihypertensive reported that they would be willing to take that specific antihypertensive starting as early as mid-life. Concerns reported were potential side effects, lack of evidence of effectiveness, blood pressure being normal or low, and medication cost. Analysis of free-text responses revealed themes of concerns regarding evidence of effectiveness and health priorities.

Entities:  

Keywords:  Alzheimer’s disease; antihypertensive agents; dementia; primary prevention

Year:  2019        PMID: 30814348     DOI: 10.3233/JAD-181080

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  3 in total

1.  Do Patient Concerns About Antihypertensive Use For Dementia Prevention Vary By Current Use Of Antihypertensive?

Authors:  Woojung Lee; Shelly L Gray; Douglas Barthold; Paul K Crane; Eric B Larson; Zachary A Marcum
Journal:  Patient Prefer Adherence       Date:  2019-10-23       Impact factor: 2.711

2.  Beliefs about benefits and harms of medications and supplements for brain health.

Authors:  Zachary A Marcum; Sarah D Hohl; Douglas Barthold; Oleg Zaslavsky; Eric B Larson; Shelly L Gray
Journal:  Prev Med Rep       Date:  2020-01-25

3.  Association of Angiotensin II-Stimulating Antihypertensive Use and Dementia Risk: Post Hoc Analysis of the PreDIVA Trial.

Authors:  Jan Willem van Dalen; Zachary A Marcum; Shelly L Gray; Douglas Barthold; Eric P Moll van Charante; Willem A van Gool; Paul K Crane; Eric B Larson; Edo Richard
Journal:  Neurology       Date:  2020-11-05       Impact factor: 9.910

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.